|
1
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Owens MA, Horten BC and Da Silva MM: HER2
amplification ratios by fluorescence in situ hybridization and
correlation with immunohistochemistry in a cohort of 6556 breast
cancer tissues. Clin Breast Cancer. 5:63–69. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cobleigh MA, Vogel CL, Tripathy D, Robert
NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman
G and Slamon DJ: Multinational study of the efficacy and safety of
humanized anti-HER2 monoclonal antibody in women who have
HER2-overexpressing metastatic breast cancer that has progressed
after chemotherapy for metastatic disease. J Clin Oncol.
17:2639–2648. 1999.PubMed/NCBI
|
|
4
|
Baselga J, Tripathy D, Mendelsohn J,
Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA,
Moore J, et al: Phase II study of weekly intravenous recombinant
humanized anti-p185HER2 monoclonal antibody in patients
with HER2/neu-overexpressing metastatic breast cancer. J Clin
Oncol. 14:737–744. 1996.PubMed/NCBI
|
|
5
|
Vogel CL, Cobleigh MA, Tripathy D, Gutheil
JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF,
Burchmore M, et al: Efficacy and safety of trastuzumab as a single
agent in first-line treatment of HER2-overexpressing metastatic
breast cancer. J Clin Oncol. 20:719–726. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Slamon DJ, Leyland-Jones B, Shak S, Fuchs
H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M,
et al: Use of chemotherapy plus a monoclonal antibody against HER2
for metastatic breast cancer that overexpresses HER2. N Engl J Med.
344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yin W, Jiang Y, Shen Z, Shao Z and Lu J:
Trastuzumab in the adjuvant treatment of HER2-positive early breast
cancer patients: a meta-analysis of published randomized controlled
trials. PLoS One. 6:e210302011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Arteaga CL, Sliwkowski MX, Osborne CK,
Perez EA, Puglisi F and Gianni L: Treatment of HER2-positive breast
cancer: current status and future perspectives. Nat Rev Clin Oncol.
9:16–32. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hsieh AC and Moasser MM: Targeting HER
proteins in cancer therapy and the role of the non-target HER3. Br
J Cancer. 97:453–457. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
She QB, Chandarlapaty S, Ye Q, Lobo J,
Haskell KM, Leander KR, DeFeo-Jones D, Huber HE and Rosen N: Breast
tumor cells with PI3K mutation or HER2 amplification are
selectively addicted to Akt signaling. PLoS One. 3:e30652008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sarbassov DD, Guertin DA, Ali SM and
Sabatini DM: Phosphorylation and regulation of Akt/PKB by the
rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bozulic L, Surucu B, Hynx D and Hemmings
BA: PKBalpha/Akt1 acts downstream of DNA-PK in the DNA
double-strand break response and promotes survival. Mol Cell.
30:203–213. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bacus SS, Altomare DA, Lyass L, Chin DM,
Farrell MP, Gurova K, Gudkov A and Testa JR: AKT2 is frequently
upregulated in HER-2/neu-positive breast cancers and may contribute
to tumor aggressiveness by enhancing cell survival. Oncogene.
21:3532–3540. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Park SS and Kim SW: Activated Akt
signaling pathway in invasive ductal carcinoma of the breast:
correlation with HER2 overexpression. Oncol Rep. 18:139–143.
2007.PubMed/NCBI
|
|
16
|
Zhou X, Tan M, Stone Hawthorne V, Klos KS,
Lan KH, Yang Y, Yang W, Smith TL, Shi D and Yu D: Activation of the
Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2
overexpression predicts tumor progression in breast cancers. Clin
Cancer Res. 10:6779–6788. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tokunaga E, Kimura Y, Oki E, Ueda N,
Futatsugi M, Mashino K, Yamamoto M, Ikebe M, Kakeji Y, Baba H and
Maehara Y: Akt is frequently activated in HER2/neu-positive breast
cancers and associated with poor prognosis among hormone-treated
patients. Int J Cancer. 118:284–289. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stål O, Pérez-Tenorio G, Akerberg L,
Olsson B, Nordenskjöld B, Skoog L and Rutqvist LE: Akt kinases in
breast cancer and the results of adjuvant therapy. Breast Cancer
Res. 5:R37–R44. 2003.PubMed/NCBI
|
|
19
|
Hutchinson JN, Jin J, Cardiff RD, Woodgett
JR and Muller WJ: Activation of Akt-1 (PKB-alpha) can accelerate
ErbB-2-mediated mammary tumorigenesis but suppresses tumor
invasion. Cancer Res. 64:3171–3178. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Arboleda MJ, Lyons JF, Kabbinavar FF, Bray
MR, Snow BE, Ayala R, Danino M, Karlan BY and Slamon DJ:
Overexpression of AKT2/protein kinase Bbeta leads to up-regulation
of beta1 integrins, increased invasion, and metastasis of human
breast and ovarian cancer cells. Cancer Res. 63:196–206.
2003.PubMed/NCBI
|
|
21
|
Pérez-Tenorio G and Stål O: Activation of
AKT/PKB in breast cancer predicts a worse outcome among endocrine
treated patients. Br J Cancer. 86:540–545. 2002.PubMed/NCBI
|
|
22
|
Schmitz KJ, Otterbach F, Callies R, Levkau
B, Hölscher M, Hoffmann O, Grabellus F, Kimmig R, Schmid KW and
Baba HA: Prognostic relevance of activated Akt kinase in
node-negative breast cancer: a clinicopathological study of 99
cases. Mod Pathol. 17:15–21. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kirkegaard T, Witton CJ, McGlynn LM, Tovey
SM, Dunne B, Lyon A and Bartlett JM: AKT activation predicts
outcome in breast cancer patients treated with tamoxifen. J Pathol.
207:139–146. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vestey SB, Sen C, Calder CJ, Perks CM,
Pignatelli M and Winters ZE: Activated Akt expression in breast
cancer: correlation with p53, Hdm2 and patient outcome. Eur J
Cancer. 41:1017–1025. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Andre F, Nahta R, Conforti R, Boulet T,
Aziz M, Yuan LX, Meslin F, Spielmann M, Tomasic G, Pusztai L, et
al: Expression patterns and predictive value of phosphorylated AKT
in early-stage breast cancer. Ann Oncol. 19:315–320. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Badve S, Collins NR, Bhat-Nakshatri P,
Turbin D, Leung S, Thorat M, Dunn SE, Geistlinger TR, Carroll JS,
Brown M, et al: Subcellular localization of activated AKT in
estrogen receptor-and progesterone receptor-expressing breast
cancers: potential clinical implications. Am J Pathol.
176:2139–2149. 2010. View Article : Google Scholar
|
|
27
|
Esteva FJ, Guo H, Zhang S, Santa-Maria C,
Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN and Yu D: PTEN,
PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab
response and survival in patients with HER2-positive metastatic
breast cancer. Am J Pathol. 177:1647–1656. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu Y, Mohamed H, Chillar R, Ali I, Clayton
S, Slamon D and Vadgama JV: Clinical significance of Akt and
HER2/neu overexpression in African-American and Latina women with
breast cancer. Breast Cancer Res. 10:R32008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo
P, Hu LS, Anderson MJ, Arden KC, Blenis J and Greenberg ME: Akt
promotes cell survival by phosphorylating and inhibiting a Forkhead
transcription factor. Cell. 96:857–868. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Boehme KA, Kulikov R and Blattner C: p53
stabilization in response to DNA damage requires Akt/PKB and
DNA-PK. Proc Natl Acad Sci USA. 105:7785–7790. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ahn JY, Liu X, Liu Z, Pereira L, Cheng D,
Peng J, Wade PA, Hamburger AW and Ye K: Nuclear Akt associates with
PKC-phosphorylated Ebp1, preventing DNA fragmentation by inhibition
of caspase-activated DNase. EMBO J. 25:2083–2095. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou BP, Liao Y, Xia W, Spohn B, Lee MH
and Hung MC: Cytoplasmic localization of p21Cip1/WAF1 by
Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat
Cell Biol. 3:245–252. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Viglietto G, Motti ML, Bruni P, Melillo
RM, D’Alessio A, Califano D, Vinci F, Chiappetta G, Tsichlis P,
Bellacosa A, et al: Cytoplasmic relocalization and inhibition of
the cyclin-dependent kinase inhibitor p27Kip1 by
PKB/Akt-mediated phosphorylation in breast cancer. Nat Med.
8:1136–1144. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Le XF, Pruefer F and Bast RC Jr:
HER2-targeting antibodies modulate the cyclin-dependent kinase
inhibitor p27Kip1 via multiple signaling pathways. Cell
Cycle. 4:87–95. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Simoncini T, Hafezi-Moghadam A, Brazil DP,
Ley K, Chin WW and Liao JK: Interaction of oestrogen receptor with
the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature.
407:538–541. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Irie HY, Pearline RV, Grueneberg D, Hsia
M, Ravichandran P, Kothari N, Natesan S and Brugge JS: Distinct
roles of Akt1 and Akt2 in regulating cell migration and
epithelial-mesenchymal transition. J Cell Biol. 171:1023–1034.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yoeli-Lerner M, Yiu GK, Rabinovitz I,
Erhardt P, Jauliac S and Toker A: Akt blocks breast cancer cell
motility and invasion through the transcription factor NFAT. Mol
Cell. 20:539–550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Datta SR, Brunet A and Greenberg ME:
Cellular survival: a play in three Akts. Genes Dev. 13:2905–2927.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xuan Nguyen TL, Choi JW, Lee SB, Ye K, Woo
SD, Lee KH and Ahn JY: Akt phosphorylation is essential for nuclear
translocation and retention in NGF-stimulated PC12 cells. Biochem
Biophys Res Commun. 349:789–798. 2006.PubMed/NCBI
|
|
40
|
Kikani CK, Dong LQ and Liu F: ‘New’-clear
functions of PDK1: beyond a master kinase? J Cell Biochem.
96:1157–1162. 2005.
|
|
41
|
Yoo JY, Wang XW, Rishi AK, Lessor T, Xia
XM, Gustafson TA and Hamburger AW: Interaction of the PA2G4 (EBP1)
protein with ErbB-3 and regulation of this binding by heregulin. Br
J Cancer. 82:683–690. 2000.PubMed/NCBI
|
